REG - AstraZeneca PLC - AstraZeneca announces sale of West Chester site

AstraZenecaAnnouncement

30/11/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd9775Ha&default-theme=true

RNS Number : 9775H  AstraZeneca PLC  30 November 2022

30 November 2022 07:05 GMT

 

AstraZeneca announces sale of its West Chester, Ohio (US) manufacturing site

 

National Resilience, Inc. to expand site and support future growth of its
medicines manufacturing capabilities

 

AstraZeneca today announces the sale of its West Chester site in Ohio, US, to
National Resilience, Inc. (Resilience), a technology-focused manufacturing
company dedicated to broadening access to complex medicines.

 

Andrew Wirths, Senior Vice President, Americas Supply Region, AstraZeneca,
said: "As part of our long-term strategy to ensure our global supply network
remains fit for the future, we are continuously optimising our manufacturing
footprint to meet the evolving needs of our pipeline and portfolio. The
transfer of our West Chester site to Resilience will enable the continued
supply of AstraZeneca medicines to patients, as well as the continued
employment for more than 500 people working at the West Chester site. I'm
encouraged by Resilience's plans to transform the site into their drug product
centre of excellence."

 

"The West Chester site will play an important role in the delivery of our
mission to broaden access to complex medicines, protect biopharmaceutical
supply chains, and strengthen domestic preparedness," said Rahul Singhvi,
Sc.D, Chief Executive Officer of Resilience. "I'm confident that West
Chester's premier capabilities, including the talented employees who are
joining Resilience, will help us expand our business in new directions."

 

AstraZeneca expects to complete the sale in the first quarter of 2023, with a
phased transition of services.

 

Notes

 

About AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts
For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to
broadening access to complex medicines. Founded in 2020, the company is
building a sustainable network of high-tech, end-to-end manufacturing
solutions to ensure the treatments of today and tomorrow can be made quickly,
safely, and at scale. Resilience seeks to free its partners to focus on the
discoveries that improve patients' lives by continuously advancing the science
of biopharmaceutical manufacturing and development. For more information,
visit www.Resilience.com
(https://protect-de.mimecast.com/s/NxevCpZ4qntxKEYyRuD1exd?domain=cts.businesswire.com)
and follow us on social media: @IncResilience
(https://protect-de.mimecast.com/s/lUHtCqQgrou7l6qRMUQC85a?domain=cts.businesswire.com)
on Twitter and Resilience
(https://protect-de.mimecast.com/s/_ma3Cr2jvpCDo3g6BcyjAuH?domain=cts.businesswire.com)
on LinkedIn.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKCBDABDDODB